Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirelizumab plus Surgery for Recurrent Nasopharyngeal Carcinoma
NCT05092217Phase 2Unknown
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05092217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092217.